Neurocrine Biosciences, Inc. (OQ:NBIX)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 6027 EDGEWOOD BEND COURT
SAN DIEGO CA 92130
Tel: 1-858-6177143
Website: https://www.neurocrine.com
IR: See website
<
Key People
Kevin C. Gorman
Chief Executive Officer, Director
Darin M. Lippoldt
Chief Legal Officer, Corporate Secretary
Matthew C. Abernethy
Chief Financial Officer
Julie S. Cooke
Chief Human Resource Officer
Jude Onyia
Chief Scientific Officer
Eric S. Benevich
Chief Commercial Officer
David Warren Boyer
Chief Corporate Affairs Officer
Ingrid Delaet
Chief Regulatory Officer
Kyle W. Gano
Chief Business Development and Strategy Officer
Eiry Wyn Roberts
Chief Medical Officer
   
Business Overview
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is engaged in discovering and developing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its commercial products include INGREZZA, ALKINDI, EFMODY, Orilissa and Oriahnn. INGREZZA is marketed as DYSVAL (valbenazine) in Japan and REMLEAS (valbenazine) in other select Asian markets, where Mitsubishi Tanabe Pharma Corporation retains commercialization rights. ALKINDI is marketed as ALKINDI SPRINKLE (hydrocortisone) in the United States, where Eton Pharmaceuticals, Inc. retains commercialization rights.
Financial Overview
For the three months ended 31 March 2024, Neurocrine Biosciences, Inc. revenues increased 23% to $515.3M. Net income totaled $43.4M vs. loss of $76.6M. Revenues reflect Collaboration revenue increase of 24% to $6.3M. Net Income reflects Acquired in-process research and develop decrease of 96% to $6M (expense), Investment income and other, net increase from $9.8M to $23.4M (income).
Employees: 1,448 as of Mar 31, 2024
Reporting Currency: U.S. Dollars
Enterprise value: $12,082M as of Mar 31, 2024
Annual revenue (TTM): $1,982M as of Mar 31, 2024
EBITDA (TTM): $492.90M as of Mar 31, 2024
Net annual income (TTM): $369.70M as of Mar 31, 2024
Free cash flow (TTM): $614.40M as of Mar 31, 2024
Net Debt Last Fiscal Year: N/A
Shares outstanding: 100,637,227 as of Apr 25, 2024
Index Membership: S&P 400 Mid Cap
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.